Over the past 12 months, 13 insiders at PTC THERAPEUTICS, INC. filed 218 open-market SEC Form 4 transactions on PTCT: 0 purchases worth $0 and 218 sales worth $58.4M. Insiders have been net sellers over this period. The most recent filing was on Jul 9, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 9, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 2.5K | $90.25 | $222K |
| Jul 9, 26 | Mary L. Smith | SELL | 10.0K | $90.00 | $900K |
| Jul 7, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 11.4K | $89.44 | $1.0M |
| Jul 6, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 10.1K | $87.03 | $871K |
| Jul 6, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 1.0K | $86.38 | $87K |
| Jun 26, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 7.7K | $85.26 | $658K |
| Jun 25, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 11.3K | $87.00 | $981K |
| Jun 24, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 4.9K | $85.03 | $419K |
| Jun 22, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 12.1K | $81.21 | $978K |
| Jun 17, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 6.6K | $79.25 | $518K |
| Jun 10, 26 | Eric PauwelsCHIEF BUSINESS OFFICER | SELL | 17.6K | $75.00 | $1.3M |
| May 15, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 2.4K | $72.67 | $170K |
| May 8, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 1.9K | $79.31 | $151K |
| Apr 6, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 1.4K | $69.75 | $101K |
| Apr 2, 26 | Lee Scott GoldenEVP & CHIEF MEDICAL OFFICER | SELL | 829 | $67.99 | $56K |
| Mar 12, 26 | Matthew B. KleinCHIEF EXECUTIVE OFFICER | SELL | 2.7K | $64.08 | $171K |
| Mar 10, 26 | Stephanie OkeyDirector | SELL | 14.0K | $70.00 | $980K |
| Mar 5, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 4.0K | $63.38 | $253K |
| Mar 5, 26 | Lee Scott GoldenEVP & CHIEF MEDICAL OFFICER | SELL | 10.0K | $63.38 | $634K |
| Mar 5, 26 | Stephanie OkeyDirector | SELL | 6.3K | $63.38 | $401K |
| Feb 19, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 1.6K | $69.82 | $114K |
| Feb 18, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 3.1K | $69.36 | $212K |
| Feb 18, 26 | Lee Scott GoldenEVP & CHIEF MEDICAL OFFICER | SELL | 2.5K | $69.36 | $172K |
| Feb 18, 26 | Pierre GravierCHIEF FINANCIAL OFFICER | SELL | 3.0K | $69.36 | $208K |
| Feb 18, 26 | Matthew B. KleinCHIEF EXECUTIVE OFFICER | SELL | 7.4K | $69.36 | $511K |
| Feb 18, 26 | Eric PauwelsCHIEF BUSINESS OFFICER | SELL | 3.0K | $69.36 | $209K |
| Feb 18, 26 | Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER | SELL | 2.5K | $69.36 | $173K |
| Feb 18, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 3.1K | $69.36 | $214K |
| Feb 17, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 2.8K | $70.13 | $195K |
| Jan 12, 26 | Eric PauwelsCHIEF BUSINESS OFFICER | SELL | 1.0K | $78.70 | $81K |
| Jan 9, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 1.5K | $79.52 | $118K |
| Jan 9, 26 | Eric PauwelsCHIEF BUSINESS OFFICER | SELL | 1.7K | $77.41 | $133K |
| Jan 8, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 881 | $76.45 | $67K |
| Jan 8, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 2.5K | $77.07 | $190K |
| Jan 8, 26 | Lee Scott GoldenEVP & CHIEF MEDICAL OFFICER | SELL | 866 | $76.45 | $66K |
| Jan 8, 26 | Matthew B. KleinCHIEF EXECUTIVE OFFICER | SELL | 2.5K | $76.45 | $192K |
| Jan 8, 26 | Eric PauwelsCHIEF BUSINESS OFFICER | SELL | 2.6K | $76.98 | $196K |
| Jan 8, 26 | Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER | SELL | 1.0K | $76.45 | $79K |
| Jan 7, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 1.0K | $77.48 | $79K |
| Jan 7, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 1.6K | $78.98 | $126K |
| Jan 7, 26 | Lee Scott GoldenEVP & CHIEF MEDICAL OFFICER | SELL | 642 | $77.48 | $50K |
| Jan 7, 26 | Matthew B. KleinCHIEF EXECUTIVE OFFICER | SELL | 3.0K | $77.48 | $234K |
| Jan 7, 26 | Eric PauwelsCHIEF BUSINESS OFFICER | SELL | 1.4K | $77.48 | $105K |
| Jan 7, 26 | Christine Marie UtterSVP, CHIEF ACCOUNTING OFFICER | SELL | 1.2K | $77.45 | $96K |
| Jan 6, 26 | Neil Gregory AlmsteadCHIEF TECHNICAL OPS OFFICER | SELL | 1.3K | $76.95 | $98K |
| Jan 6, 26 | Mark Elliott BouldingEXEC. VP AND CLO | SELL | 1.7K | $76.95 | $134K |
| Jan 6, 26 | Lee Scott GoldenEVP & CHIEF MEDICAL OFFICER | SELL | 1.3K | $76.95 | $103K |
| Jan 6, 26 | Pierre GravierCHIEF FINANCIAL OFFICER | SELL | 2.1K | $76.95 | $165K |
| Jan 6, 26 | Matthew B. KleinCHIEF EXECUTIVE OFFICER | SELL | 5.1K | $76.95 | $396K |
| Jan 6, 26 | Eric PauwelsCHIEF BUSINESS OFFICER | SELL | 1.8K | $76.95 | $138K |
Over the past 12 months, insiders at PTC THERAPEUTICS, INC. filed 0 open-market purchases worth $0 and 218 sales worth $58.4M on PTCT, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 9, 26.
13 different insiders at PTC THERAPEUTICS, INC. filed open-market SEC Form 4 transactions on PTCT over the last 12 months.
InsiderTape plots every PTCT insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every PTC THERAPEUTICS, INC. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →